loading...| Preferred Name |
basiliximab |
|
| Synonyms |
Simulect |
|
| Definitions |
A recombinant, chimeric, human-murine monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha) with immunosuppressant activity. Basiliximab selectively binds to and blocks IL-2R alpha, expressed on the surface of activated T-lymphocytes, thereby preventing interleukin-2 binding and inhibiting the interleukin-2-mediated activation of lymphocytes. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C52186" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C52186" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000459956 |
|
| altLabel |
Simulect SDZ-CHI-621 |
|
| cui |
C0723325 C0757163 C0676831 |
|
| DATE FIRST PUBLISHED |
2005-12-22 |
|
| Date last modified |
2006-07-27 |
|
| definition |
A recombinant, chimeric, human-murine monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha) with immunosuppressant activity. Basiliximab selectively binds to and blocks IL-2R alpha, expressed on the surface of activated T-lymphocytes, thereby preventing interleukin-2 binding and inhibiting the interleukin-2-mediated activation of lymphocytes. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C52186" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C52186" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C52186 |
|
| notation |
CDR0000459956 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
basiliximab |
|
| tui |
T109 T116 T129 T130 T121 |